erlotinib hydrochloride has been researched along with Esophageal Squamous Cell Carcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter, MA; Petty, RD; Spender, LC | 1 |
| Bian, X; Chen, M; Ding, L; Du, D; Hu, W; Jiang, W; Jing, Z; Li, D; Lian, X; Liu, Q; Luo, H; Ma, L; Tan, B; Wang, L; Wu, S; Xia, B; Xie, C; Xie, R; Zhang, H; Zheng, A | 1 |
| Amanuma, Y; Chiba, T; Ida, T; Kikuchi, O; Matsubara, J; Miyamoto, S; Muto, M; Nakagawa, H; Nakai, Y; Natsuizaka, M; Ohashi, S; Seno, H; Yamada, A; Yoshioka, M | 1 |
| Lordick, F | 1 |
| Hatanaka, Y; Kagawa, S; Kinugasa, H; Komatsu, Y; Kubota, Y; Maehara, O; Marukawa, K; Nakagawa, H; Natsuizaka, M; Ohashi, S; Ohnishi, S; Sakamoto, N; Sato, F; Shimizu, Y; Suda, G; Terashita, K; Whelan, KA | 1 |
| Bass, AJ; Chen, T; Diehl, JA; Liu, JB; Nagaraja, A; Pectasides, E; Rustgi, AK; Sanchez-Vega, F; Sicinska, E; Stachler, M; Wong, G; Wong, KK; Wu, Z; Xu, X; Zhang, H; Zhou, J | 1 |
| Chen, Y; Ge, F; Jia, R; Jin, Y; Lin, L; Liu, J; Liu, R; Wang, Y; Xu, J; Zhao, C | 1 |
2 trial(s) available for erlotinib hydrochloride and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel | 2020 |
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
5 other study(ies) available for erlotinib hydrochloride and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Precision Medicine | 2020 |
Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Topics: Animals; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward.
Topics: Chemoradiotherapy; Epithelial Cells; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans | 2018 |
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Homeodomain Proteins; Humans; Neoplastic Stem Cells; Spheroids, Cellular; Transcription Factors; Tumor Burden; Tumor Cells, Cultured; Zinc Finger E-box-Binding Homeobox 1 | 2015 |
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Amplification; Humans; Mice; Mitogen-Activated Protein Kinases; Phenotype; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |